Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 76

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 76
---
2024, Mr. Verratti was granted 58,630 PSUs, which are subject to the achievement of revenue and adjusted EPS targets based on fiscal year 2026 results and relative total stockholder return targets over a three-year measurement period ending December 31, 2026, and 58,631 RSUs, which are subject to time-based vesting requirements (33.3% vesting each year over a three-year period).

On February 24, 2025, the Board appointed Mark S. Verratti as our Chief Operating Officer, effective on the Transition Effective Date. In connection with his new appointment, we entered into the Verratti Employment Agreement setting forth Mr. Verratti’s compensation consisting of an annual base salary of $660,000, annual target cash bonus equal to 75% of his annual base salary upon achievement of goals to be established by the CHCC or our Chief Executive Officer each fiscal year and eligibility to participate in our annual long-term incentive compensation program. The Verratti Employment Agreement also provides for a one-time grant of 105,785 RSUs in connection with his promotion which are subject to performance-based vesting in four equal installments based upon the achievement of certain stock price targets, provided that no portion of these RSUs will vest earlier than the first anniversary of the Transition Effective Date. The Verratti Employment Agreement also provides that Mr. Verratti will be eligible for a grant in 2025 of an additional equity award of restricted stock units valued at up to $2,750,000 in accordance with our annual equity grant cycle, with such award consisting of (i) 50% RSUs and (ii) 50% PSUs, as determined by the CHCC in its sole discretion.

Dr. Muzzey joined the predecessor to Myriad Women's Health in 2014 and served in various roles, including as Senior Director, Scientific Affairs. He was appointed Senior Director of Clinical Development in August 2018 and served in that role until September 2019, when he was appointed Vice President of Bioinformatics, a position he held until December 2021. In January 2022, he was appointed Senior Vice President, R&D and Interim Chief Scientific Officer. On April 14, 2022, he was promoted to Chief Scientific Officer. As determined by our CHCC, he received a salary of $499,350 for the 2024 fiscal year. His incentive bonus for the 2024 fiscal year was $265